Veritable’s Enzo Biochem, Inc. ENZ Stock Holding History

Veritable’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-99,675	Closed	-$206K	–	914
2022 Q2	$206K	Buy	+99,675	New	+$246K	﹤0.01%	812

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCA

VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Veritable's ENZ Position: Q3 2022 in Review

Veritable sold out of Enzo Biochem, Inc. (ENZ) in Q3 2022, closing a stake of 99,675 shares — an estimated $206K sold.

Veritable first reported a position in ENZ in Q2 2022 and held it in 1 quarter. The position peaked at $206K in Q2 2022. 49 funds tracked by Wall St. Rank hold ENZ as of Q3 2022.

Veritable reported no remaining Enzo Biochem, Inc. position as of Q3 2022 after selling out during the quarter.
Veritable sold 99,675 Enzo Biochem, Inc. shares in Q3 2022, an estimated $206K.
Veritable first reported a position in Enzo Biochem, Inc. in Q2 2022 and held it in 1 quarter.
Veritable's Enzo Biochem, Inc. position peaked at $206K in Q2 2022.
49 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2022.

Based on Veritable's 13F filing for Q3 2022, filed 14 Nov 2022.